Advantage Solutions (NASDAQ:ADV) reported quarterly sales of $981.10 million which missed the analyst consensus estimate of $981.32 million by 0.02 percent. This is a 15.43 percent increase over sales of $849.95 million the same period last year.
Novavax’s Nuvaxovid Receives Full Marketing Authorization In The EU For The Prevention Of COVID
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Marketing Authorization includes use of Nuvaxovid™ as a primary series in individuals aged 12 and older and
